FLT3 and acute myeloid leukemia: A number of retrospective studies have demonstrated a reduced risk of disease relapse in those patients allografted for FLT3 ITD+ AML, who received post‐transplant sorafenib maintenance (Brunner et al., 2016), but do not currently justify the routine administration of FLT3 inhibitors in this patient group.